Compare D R Horton Inc (DHI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Sana Biotechnology Inc — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: D R Horton Inc is far larger — about 45.4× Sana Biotechnology Inc's market cap, and D R Horton Inc pays a 1.33% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Sana Biotechnology Inc for 23 Days on average.
| DHI | SANA | |
|---|---|---|
Market Cap | $37.99B | $836.71M |
Volume | 2,974,460 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $5.92 |
52-Week Low | $132.53 | $2.68 |
Typical Hold Time | 46 Days | 23 Days |
Enterprise Value | $43.09B | $749.96M |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $134.88, up 1.2% on the day, with a bearish technical signal and neutral oscillators. The stock has beaten earnings estimates in recent quarters, with a P/E of 12.95 and net income margin of 9.15%. Recent news highlights pressure from rising mortgage rates, with the 30-year fixed rate potentially spiking to 9% according to Selma Hepp on CNBC (2026-09-28), impacting homebuilder sentiment.
The outlook is mixed: strong fundamentals and analyst consensus price target of $156.57 offer upside, but macroeconomic risks from interest rates and housing market weakness pose headwinds. Earnings growth remains a key catalyst, yet affordability concerns could dampen near-term performance.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
